Table 4.
Stepwise regression modelsa relating baseline levels of fatty acids and change in peripheral nerve functional parameter over three year follow-up
| NV velocity (m/s) | Amplitude of CMAP (mV) | |||||
|---|---|---|---|---|---|---|
| <65 years, (n = 230) | 65–84 years, (n = 569) | >85 years, (n = 26) | <65 years, (n = 230) | 65–84 years, (n = 569) | >85 years, (n = 26) | |
| Saturated fatty acids (%) | 0.14 (0.15) | −0.13 (0.07)* | −0.12 (0.16) | −0.04 (0.13) | −0.11 (0.06)* | −0.16 (0.12) |
| Monounsaturated fatty acids (%) | 0.18 (0.13) | −0.10 (0.06) | 0.09 (0.12) | 0.30 (0.12)* | 0.004 (0.05) | 0.04 (0.09) |
| Polyunsaturated fatty acids (%) | 0.21 (0.10)* | −0.01 (0.06) | −0.26 (0.10) | 0.20 (0.09)* | 0.08 (0.04)* | 0.04 (0.08) |
| Omega-6 fatty acids (mg/l) | 0.14 (0.11) | 0.03 (0.06) | 0.04 (0.73) | 0.17 (0.09)* | 0.11 (0.05)* | 0.02 (0.78) |
| Linoleic acid (mg/l) | 0.07 (0.09) | 0.07 (0.07) | 0.10 (0.13) | 0.17 (0.08)* | 0.10 (0.05)* | 0.09 (0.03)* |
| Arachidonic acid (mg/l) | −0.15 (0.19) | −0.06 (0.11) | 0.10 (0.59) | 0.10 (0.17) | 0.18 (0.09)* | 0.14 (0.15) |
| Omega-3 fatty acids (mg/l) | 1.01 (0.32) | 0.73 (0.54) | 0.15 (0.98) | 1.26 (0.91) | 0.76 (0.44)* | 0.19 (0.75) |
| Linolenic acid (mg/l) | 1.92 (1.29) | 0.27 (0.75) | 1.56 (1.40) | 0.76 (1.17) | 0.49 (0.64) | 1.33 (0.20) |
| Eicosapentaenoic acid (mg/l) | 0.81 (1.92) | 0.41 (0.87) | 0.14 (1.59) | 1.02 (1.74) | 0.12 (0.70) | 0.53 (1.21) |
| Docosahexaenoic acid (mg/l) | 0.29 (0.41) | 0.62 (0.26)* | 0.46 (0.16)* | 0.47 (0.37) | 0.40 (0.21)* | 0.35 (0.34) |
| Ratio n-6/n-3 | 0.11 (0.11) | 0.12 (0.06)* | 0.04 (0.13) | −0.06 (0.10) | −0.04 (0.05) | −0.06 (0.10) |
Values are given as B(SD).
*
P < 0.05.
a
Each coefficient is from a specific model adjusted for the baseline nerve functional parameters (NVC and CMAP) and age, sex, age-sex interaction, body mass index, total cholesterol, triglycerides, diabetes, and peripheral artery diseases.